Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists

Gang Hu; David J Varisco; Sayan Das; C Russell Middaugh; Francesca Gardner; Robert K Ernst; Wendy L Picking; William D Picking

doi:10.1016/j.heliyon.2023.e18119

Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists

Heliyon. 2023 Jul 8;9(7):e18119. doi: 10.1016/j.heliyon.2023.e18119. eCollection 2023 Jul.

Authors

Gang Hu¹, David J Varisco², Sayan Das², C Russell Middaugh¹, Francesca Gardner², Robert K Ernst², Wendy L Picking^{1

3}, William D Picking^{1

3

4}

Affiliations

¹ Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA.
² Department of Microbial Pathogenesis, University of Maryland, Baltimore, MD 21201, USA.
³ Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.
⁴ Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA.

Abstract

Toll-like receptor (TLR) agonists are recognized as potential immune-enhancing adjuvants and are included in several licensed vaccines. Monophosphoryl lipid A (MPL®, GlaxoSmithKline) is one such TLR4 agonist that has been approved for use in human vaccines, such as Cervarix and Shingrix. Due to the heterogeneous nature of biologically derived MPL and the need for safer and more potent adjuvants, our groups have developed the novel TLR4 agonist candidates, BECC438 and BECC470 using the Bacterial Enzymatic Combinatorial Chemistry (BECC) platform. BECC438 and BECC470 have been included in studies to test their adjuvant potential and found to be effective in vaccines against both viral and bacterial disease agents. Here, we report detailed biophysical characterization of BECC438 and BECC470 purified from a biological source (BECC438b and BECC470b, respectively) and synthesized chemically (BECC438s and BECC470s, respectively). Both BECC438s and BECC470s have identical acyl chain configurations, BECC438s is bis-phosphorylated and BECC470s is mono-phosphorylated with the removal of the 4' phosphate moiety. We determined the phase transition temperatures for the acyl chains of BECC438b and BECC470b and found them to be different from those exhibited by their synthetic counterparts. Furthermore, the phosphate groups of BECC438b and BECC470b are more highly hydrated than are those of BECC438s and BECC470s. In addition to exploring the BECC molecules' biophysical features in aqueous solution, we explored potential formulation of BECC438 and BECC470 with the aluminum-based adjuvant Alhydrogel and as part of an oil-in-water emulsion (Medimmune Emulsion or ME). All of the lipid A analogues could be fully absorbed to Alhydrogel or incorporated onto ME. Surprisingly, the BECC470s molecule, unlike the others, displayed a nearly baseline signal when monitored using a Limulus amebocyte lysate (LAL) endotoxin detection system. Despite this, it was shown to behave as an agonist for human and mouse TLR4 when tested using multiple cell-based systems. This work paves the way for further formulation optimization of two chemically defined TLR4 agonists that are showing great promise as vaccine adjuvants.

Keywords: Adjuvant; Bacterial enzymatic combinatorial chemistry (BECC); Lipid a; Monophosphoryl lipid a; TLR4 agonist.